Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC -0.27%91 Interest Coverage is 167.29 as of Mar. 2026, which is 104% above its 10-year median of 82.02. GuruFocus rates XPAE:BPC with a GF Score™ of 91/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks better than 85.3% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Birzeit Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was $2.34 Mil. Birzeit Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was $-0.01 Mil.
Birzeit Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 167.29.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Birzeit Pharmaceutical Co has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Birzeit Pharmaceutical Co's Interest Coverage or its related term are showing as below:
XPAE:BPC'
s Interest Coverage Range Over the Past 10 Years
Min: 29.09 Med: 82.02 Max: No Debt
Current: 193.12
XPAE:BPC's Interest Coverage is ranked better than 85.3% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs XPAE:BPC: 193.12
Birzeit Pharmaceutical Co (XPAE:BPC) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Birzeit Pharmaceutical Co Interest Coverage Related Terms
Birzeit Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XPAE:BPC vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Interest Coverage falls into.
Birzeit Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a Interest Coverage of 167.29 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Birzeit Pharmaceutical Co and its competitors. This is 104% above median its historical median of 82.02. Over the past decade, Birzeit Pharmaceutical Co's Interest Coverage has ranged from 29.09 to 10,000.00. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #101 out of 687 companies in the Drug Manufacturers industry, placing it in the top 14.7%.
Is Birzeit Pharmaceutical Co's Interest Coverage too high?
Birzeit Pharmaceutical Co's current Interest Coverage of 167.29 is 104% above median its 10-year median of 82.02. Over the past 10 years, this metric has ranged from a low of 29.09 to a high of 10,000.00. The Drug Manufacturers industry median Interest Coverage is 12.75. Birzeit Pharmaceutical Co's value of 167.29 is 1212.1% above this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #101 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #101 out of 687 companies for Interest Coverage. This places Birzeit Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Birzeit Pharmaceutical Co's value of 167.29 is 1212.1% above this benchmark. Historically, Birzeit Pharmaceutical Co's own Interest Coverage has ranged from 29.09 to 10,000.00 over the past decade. While the company's 10-year median is 82.02 vs. the industry median of 12.75, Birzeit Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current Interest Coverage of 167.29 is 1212.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current Interest Coverage is 167.29, which is 104% above median its own 10-year median of 82.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current Interest Coverage is 167.29, which is 104% above median its 10-year median of 82.02 and 1212.1% above the Drug Manufacturers industry median of 12.75. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Interest Coverage is 167.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
Interest Coverage: 167.29 (104% above median its 10-year median of 82.02)
GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
Industry Position: 1212.1% above the Drug Manufacturers median (#101 of 687)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score
Get the complete analysis for XPAE:BPC
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
